Gossamer Bio (4GB) Price & Analysis

5 Followers

4GB Stock Chart & Stats

€0.20

€0.05(35.37%)

At close: Jul 28 4:00 PM EDT

€0.20

€0.05(35.37%)

Day’s Range― - ―

52-Week Range€0.11 - €3.17

Previous CloseN/A

Volume52.17K

Average Volume (3M)300.00

Market Cap

€85.75M

Enterprise Value€37.16

Total Cash (Recent Filing)€57.03M

Total Debt (Recent Filing)€39.10M

Price to Earnings (P/E)―

Beta-0.12

Next Earnings

Nov 05, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.57

Shares Outstanding488,846,700

10 Day Avg. Volume900

30 Day Avg. Volume300

Financial Highlights & Ratios

PEG Ratio-0.02

Price to Book (P/B)-5.77

Price to Sales (P/S)14.62

P/FCF Ratio-4.13

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.92

Price Target Upside358.44% Upside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)-0.2

Revenue Forecast (FY)€32.93M

Bulls Say, Bears Say

Bulls Say

Clinical Efficacy And Mechanistic SupportConsistent directional benefits across the primary measure, secondary endpoints and imaging biomarkers strengthen the clinical rationale for seralutinib. These signals may support development and regulatory discussions despite the prespecified statistical miss.

Regulatory Path And Product ControlFull control of development, manufacturing and pricing gives Gossamer greater authority over seralutinib’s economics and strategy. The planned NDA creates a defined regulatory pathway and potential future commercialization opportunity in pulmonary hypertension.

Capital Committed To DevelopmentCommitted and approval-linked financing could extend funding beyond the current runway and support late-stage development and potential commercialization. Greater liquidity may reduce immediate disruption risk while Gossamer advances seralutinib through review.

Bears Say

Persistent Losses And Cash BurnThe company lacks recurring product revenue and continues to consume substantial cash while reporting deep losses and negative equity. This weak financial base limits flexibility and leaves long-term execution dependent on external financing or successful partnering.

Primary Endpoint Statistical ShortfallMissing the study’s prespecified threshold creates meaningful regulatory and interpretive uncertainty around the pivotal evidence package. Supportive secondary and mechanistic findings may help, but they do not eliminate approval and label-scope risk.

Dilution And Secured Financing BurdenThe financing structure improves maturity flexibility but shifts value toward creditors and new security holders through interest, liens, conversion rights and warrants. Potential dilution can constrain per-share economics and complicate future capital raising.

Gossamer Bio News

Gossamer Bio announces upt to $250M structured private placement

Gossamer Bio (GOSS) entered into a securities purchase agreement with certain new and existing institutional investors for a...

7d ago

GOSS

Gossamer Bio reports Q2 EPS (8c), consensus (12c)

Cash, cash equivalents and marketable securities totaled $57.0 million as of June 30, 2026. Gossamer expects the combination...

12d ago

GOSS

Gossamer Bio price target lowered to $4 from $15 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Gossamer Bio (GOSS) to $4 from $15...

12d ago

GOSS

Gossamer Bio Amends Charter for New Preferred Financing

Gossamer Bio ( ($GOSS) ) has provided an announcement. On August 24, 2026, Gossamer Bio, Inc. amended its...

1d ago

GOSS

Gossamer Bio Secures Major Seralutinib Regulatory Financing Deal

Gossamer Bio ( ($GOSS) ) has shared an announcement. On August 20, 2026, Gossamer Bio entered into a...

7d ago

GOSS

GOSS Earnings this Week: How Will it Perform?

Gossamer Bio (GOSS) is scheduled to report 2nd quarter earnings on 08/11/2026. Regarding Q2 estimates, Wall Street analysts...

19d ago

GOSS

OTLK, HBAN, CORT, CAPR, GOSS Trending With Analysts

Analysts are intrested in these 5 stocks: ( ($OTLK) ), ( ($HBAN) ), ( ($CORT) ), ( ($CAPR)...

27d ago

CAPR

CORT

Gossamer Bio upgraded to Outperform from Market Perform at Leerink

Leerink upgraded Gossamer Bio (GOSS) to Outperform from Market Perform with an unchanged $1 price target after the...

1M ago

GOSS

Gossamer Bio Reclaims Seralutinib Rights and Control

Gossamer Bio ( ($GOSS) ) has issued an announcement. On July 23, 2026, Gossamer Bio terminated its collaboration...

1M ago

GOSS

Morning Movers: Ensign Group surges following second quarter results

Stock futures are sharply higher Monday as investors return from the weekend encouraged by easing geopolitical tensions and...

1M ago

AMR

AZN

Gossamer announces FDA regulatory update, reacquisition of Seralutinib rights

Gossamer Bio (GOSS) announced a series of regulatory, strategic, and corporate updates. Following a productive Pre-NDA Type B...

1M ago

GOSS

Gossamer Bio Sets Conversion Terms for Convertible Notes

Gossamer Bio ( ($GOSS) ) has provided an update. On July 1, 2026, Gossamer Bio announced the initial...

2M ago

GOSS

Gossamer Bio announces determination of conversion rate for senior secured notes

Gossamer Bio (GOSS) announced that the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes...

2M ago

GOSS

Gossamer Bio price target lowered to $2 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Gossamer Bio (GOSS) to $2 from $5 and keeps a...

2M ago

GOSS

4GB FAQ

What was Gossamer Bio Inc’s price range in the past 12 months?

Gossamer Bio Inc lowest stock price was €0.11 and its highest was €3.17 in the past 12 months.

What is Gossamer Bio Inc’s market cap?

Gossamer Bio Inc’s market cap is €85.75M.

When is Gossamer Bio Inc’s upcoming earnings report date?

Gossamer Bio Inc’s upcoming earnings report date is Nov 05, 2026 which is in 69 days.

How were Gossamer Bio Inc’s earnings last quarter?

Gossamer Bio Inc released its earnings results on Aug 13, 2026. The company reported -€0.069 earnings per share for the quarter, beating the consensus estimate of -€0.105 by €0.037.

Is Gossamer Bio Inc overvalued?

According to Wall Street analysts Gossamer Bio Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Gossamer Bio Inc pay dividends?

Gossamer Bio Inc does not currently pay dividends.

What is Gossamer Bio Inc’s EPS estimate?

Gossamer Bio Inc’s EPS estimate is -0.04.

How many shares outstanding does Gossamer Bio Inc have?

Gossamer Bio Inc has 488,846,700 shares outstanding.

What happened to Gossamer Bio Inc’s price movement after its last earnings report?

Gossamer Bio Inc reported an EPS of -€0.069 in its last earnings report, beating expectations of -€0.105. Following the earnings report the stock price went down -4%.

Which hedge fund is a major shareholder of Gossamer Bio Inc?

Currently, no hedge funds are holding shares in DE:4GB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Gossamer Bio Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-68.09%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Gossamer Bio (4GB) Earnings & Revenues

Historic Earnings Reports

4GB Company Deck

4GB Earnings Call

Q1 2026

0:00 / 0:00

Earnings Call Sentiment|Neutral

The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all DE:4GB earnings summaries

4GB Stock 12 Month Forecast

Average Price Target

€0.92

▲(358.44% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.71379312,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.9168793192,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.2399310368,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.24</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.151,0.27121485538461537,0.3914297107692308,0.5116445661538461,0.6318594215384615,0.7520742769230769,0.8722891323076923,0.9925039876923077,1.112718843076923,1.2329336984615384,1.3531485538461538,1.4733634092307692,1.5935782646153847,{"y":1.71379312,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.151,0.2099137937846154,0.26882758756923075,0.3277413813538461,0.3866551751384615,0.44556896892307685,0.5044827627076923,0.5633965564923077,0.622310350276923,0.6812241440615384,0.7401379378461538,0.7990517316307691,0.8579655254153846,{"y":0.9168793192,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.151,0.15784084898461537,0.16468169796923077,0.17152254695384614,0.17836339593846154,0.1852042449230769,0.1920450939076923,0.19888594289230768,0.20572679187692308,0.21256764086153845,0.21940848984615385,0.22624933883076923,0.2330901878153846,{"y":0.2399310368,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.704,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.054,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.18,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.028,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.724,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.62,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.901,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.332,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.274,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.291,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.194,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.146,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.151,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >